Companies / PER

PERCHERON THERAPEUTICS LIMITED

ASX:PERPharmaceuticals, Biotechnology & Life Sciences
1.52B shares on issueASX (delayed) · as of 28 July 2026$0.003price · delayed$4.6Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; share count grew 47% in 24 months; options/rights overhang 34% of shares

Cash runway1.0 quarters of funding
Share-count growth (24m)46.8%
Raise cadence (24m)1 cash raise
Options & rights overhang33.8% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

PERCHERON THERAPEUTICS LIMITED's ordinary share count grew 46.8% between October 2024 and April 2026, to 1.52B shares. The company raised capital once in that period via a Non-renounceable Entitlement Offer (2-for-5 pro rata) in March 2026 for proceeds of A$2.2M, bringing total disclosed proceeds over the 24-month window to A$2.2M. Options and rights on issue could convert into 515M new shares, equal to 33.8% of the current share count, with 0% in the money at the current share price and the nearest expiry in April 2028. At the March 2026 quarter the company reported A$1.3M in cash, covering 1.0 quarters of funding. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
33.8%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
1.0 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.52B per ASX (delayed) (28 July 2026).
1.18B1.30B1.43BDec 24Sept 25July 26Cash raise · 19 Mar 2026

Cash runway

1.0 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$1.3M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
3 July 20263G · unquotedPER : ORDINARY FULLY PAID1.52BAppendix 3G
1 June 20263G · unquotedORDINARY FULLY PAID1.52BAppendix 3G
30 Apr 20263H · cancellationPER : ORDINARY FULLY PAID1.52BAppendix 3H
21 Apr 20263G · unquotedORDINARY FULLY PAID1.26BAppendix 3G
21 Apr 20262A · quoted issuePER : ORDINARY FULLY PAID1.52BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$2.2M
Non-renounceable Entitlement Offer (2-for-5 pro rata)
19 Mar 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

33.8%
Total overhang · of current shares
0.0%
In the money · at current price
515.1M
Potential new shares
Apr 2028
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
15 Apr 2026James GarnerBuy21.4M10.7M$107k3Y notice
22 Dec 2025Ben Gil PriceBuy2.0M—$17k3Y notice
17 Dec 2025James GarnerBuy1.0M—$9k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

3 July 2026Notification regarding unquoted securities - PER
16 June 2026Completion of HMBD-002 Drug Substance Manufacture
1 June 2026New HMBD-002 Data Presented at ASCO Annual Meeting
1 June 2026Notification regarding unquoted securities - PER
29 May 2026Proposed issue of securities - PER
25 May 2026WHO selects proposed INN for HMBD-002
30 Apr 2026Notification of cessation of securities - PER
29 Apr 2026$PQuarterly Activities Report and Appendix 4C
21 Apr 2026Notification regarding unquoted securities - PER
21 Apr 2026Application for quotation of securities - PER
20 Apr 2026New HMBD-002 Data Presented at AACR Annual Meeting
15 Apr 2026Update - Notification regarding unquoted securities - PER
15 Apr 2026Update - Notification regarding unquoted securities - PER
15 Apr 2026Notification regarding unquoted securities - PER
15 Apr 2026Notification regarding unquoted securities - PER
15 Apr 2026Change of Director's Interest Notice
15 Apr 2026Notification regarding unquoted securities - PER
15 Apr 2026Application for quotation of securities - PER
14 Apr 2026$PResults of Entitlement Offer
1 Apr 2026Non-renounceable Entitlement Offer Closing Date Reminder

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.